


AMB-101 for Solid Tumors

AMB-101 is a next generation ADC engineered for superior properties which are supported by a robust preclinical data package. First in human trial is expected to begin in the second half of 2023.
-
Proprietary linker selectively cleaved at tumor sites
-
Excellent in vitro plasma and in vivo stability superior to gold standard and competing platforms
-
Drug Antibody Ratio (DAR) of 8
-
Proprietary and potent topoisomerase I inhibitor that is 4-10 times more potent than deruxtecan
-
Strong bystander killing effect
-
No ocular toxicity



In preclinical studies, AMB-101 demonstrated potent tumor killing activities across multiple tumor models. More importantly, AMB-101 is exceptionally stable in circulation, outperforming compounds with competing linker-payload platforms. The entire preclinical data package predicts a significantly widened therapeutic window which could potentially translate into a superior clinical profile.
AMB-101 targets a tumor associated antigen that is differentially overexpressed across a large set of solid tumors, providing basis for a broad application.
Detailed information may be presented at future scientific conferences

-
Proprietary mAb optimized for antibody drug conjugation
-
Selected to minimize unwanted off-target activity
-
Efficient internalization